Breast Cancer, Familial
|
0.400 |
Biomarker
|
disease |
CLINGEN |
DNA damage-induced activation of p53 by the checkpoint kinase Chk2.
|
10710310 |
2000 |
Breast Cancer, Familial
|
0.400 |
Biomarker
|
disease |
CLINGEN |
hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response.
|
10724175 |
2000 |
Breast Cancer, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
The high Ile(157)--> Thr(157)mutation frequency (6.5%) observed in healthy controls and the lack of other mutations suggest that CHK2 does not contribute significantly to the hereditary breast cancer or LFL-associated breast cancer risk, at least not in the Finnish population.
|
11461078 |
2001 |
Breast Cancer, Familial
|
0.400 |
Biomarker
|
disease |
CLINGEN |
Concomitant inactivation of p53 and Chk2 in breast cancer.
|
11857075 |
2002 |
Breast Cancer, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.
|
12094328 |
2002 |
Breast Cancer, Familial
|
0.400 |
Biomarker
|
disease |
CLINGEN |
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.
|
12094328 |
2002 |
Breast Cancer, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Recently, the CHEK 2 gene, involved in DNA damage and replication checkpoints, has been pointed out as a good candidate; moreover, a specific variant in this gene,1100delC, has been found to increase breast cancer susceptibility among familial breast cancer cases not attributable to mutations in BRCA1 or BRCA2 genes.
|
14618615 |
2004 |
Breast Cancer, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The low prevalence and penetrance of the exon 10 deletion mutations together with no, or an uncertain elevation in risk for other CHEK2 mutations suggests a limited relevance for CHEK2 mutations in familial breast cancer.
|
15095295 |
2004 |
Breast Cancer, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we briefly outline the molecular properties, regulation and physiological role of CHEK2, and review in more detail its defects that predispose to tumors, with particular emphasis on familial breast cancer.
|
16998506 |
2006 |
Breast Cancer, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CHEK2 1100delC is prevalent in Swedish early onset familial breast cancer.
|
17705858 |
2007 |
Breast Cancer, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Breast cancer low-penetrance allele 1100delC in the CHEK2 gene: not present in the Chinese familial breast cancer population.
|
18484200 |
2008 |
Breast Cancer, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CHEK2 1100delC was genotyped in the index cases of 369 Dutch colorectal cancer families that had been excluded for familial breast cancer.
|
18676774 |
2008 |
Breast Cancer, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the recognized breast cancer susceptibility genes BRCA1, BRCA2, TP53, ATM, and CHEK2 account for approximately 20% of hereditary breast cancer.
|
21409391 |
2011 |
Breast Cancer, Familial
|
0.400 |
Biomarker
|
disease |
CLINGEN |
Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications.
|
21542898 |
2011 |
Breast Cancer, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
CHEK2 gene mutations occur in a subset of patients with familial breast cancer, acting as moderate/low penetrance cancer susceptibility alleles.
|
21562711 |
2011 |
Breast Cancer, Familial
|
0.400 |
Biomarker
|
disease |
CLINGEN |
Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
|
21876083 |
2011 |
Breast Cancer, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated the contribution of CHEK2 mutations to non-BRCA HBC by direct sequencing of its whole coding sequence in 507 non-BRCA HBC cases and 513 controls.
|
22114986 |
2011 |
Breast Cancer, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Response to DNA damage of CHEK2 missense mutations in familial breast cancer.
|
22419737 |
2012 |
Breast Cancer, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Genotyping for the CHEK2∗1100delC mutation in a familial breast cancer setting contributes to optimal clinical surveillance in countries in which this mutation is prevalent.
|
23415889 |
2013 |
Breast Cancer, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We conclude that the tumor-specific loss of the wild-type allele is not characteristic for BC arising in CHEK2, NBN/NBS1 and BLM mutation carriers.
|
24415413 |
2014 |
Breast Cancer, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Germ line CHEK2 mutations are seen in a subset of patients with a familial breast cancer and sarcoma phenotype.
|
24595525 |
2014 |
Breast Cancer, Familial
|
0.400 |
Biomarker
|
disease |
CLINGEN |
A risk of breast cancer in women - carriers of constitutional CHEK2 gene mutations, originating from the North - Central Poland.
|
24713400 |
2014 |
Breast Cancer, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
First evidence of a large CHEK2 duplication involved in cancer predisposition in an Italian family with hereditary breast cancer.
|
24986639 |
2014 |
Breast Cancer, Familial
|
0.400 |
Biomarker
|
disease |
BEFREE |
One gene that is commonly included on NGS hereditary breast cancer panels is CHEK2.
|
25355026 |
2014 |
Breast Cancer, Familial
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, only about 20% of familial breast cancer is attributed to mutations in BRCA1 and BRCA2, while a further 5-10% are attributed to mutations in other rare susceptibility genes such as TP53, STK11, PTEN, ATM and CHEK2.
|
25736863 |
2015 |